|
25 Aug 2020 |
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
|
|
25 Aug 2020 |
Formycon and Bioeq Enroll First Patient in Phase III Study with Aflibercept Biosimilar (FYB203)
|
|
25 Aug 2020 |
New study: MassBiologics discovers antibodies that may protect against COVID-19
|
|
24 Aug 2020 |
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors
|
|
24 Aug 2020 |
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models
|
|
24 Aug 2020 |
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
|
|
22 Aug 2020 |
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma
|
|
21 Aug 2020 |
Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020
|
|
21 Aug 2020 |
SAB Biotherapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of SAB-185 for the Treatment of COVID-19
|
|
21 Aug 2020 |
Genmab Announces Plan to Transition Arzerra® (ofatumumab) to an Oncology Access Program for Chronic Lymphocytic Leukemia Patients in the U.S.
|
|
21 Aug 2020 |
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
|
|
20 Aug 2020 |
GT Biopharma Provides Update on Development of TriKE(TM) Therapeutic for Treatment of COVID-19 Infection
|
|
20 Aug 2020 |
Samsung Bioepis Receives European Commission Approval for AYBINTIO® (Bevacizumab)
|
|
19 Aug 2020 |
Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2
|
|
19 Aug 2020 |
Maverick Therapeutics Reveals Preclinical Data from COBRA™ Program, MVC-280, at Virtual Cell Engager Summit 2020
|
|
19 Aug 2020 |
Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer
|
|
19 Aug 2020 |
Genentech and Regeneron Collaborate to Significantly Increase Global Supply of REGN-COV2 Investigational Antibody Combination for COVID-19
|
|
18 Aug 2020 |
Lilly and Innovent Announce Global Expansion of TYVYT Licensing Agreement
|
|
18 Aug 2020 |
Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use
|
|
17 Aug 2020 |
Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients
|
|
17 Aug 2020 |
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China
|
|
17 Aug 2020 |
China's First Trastuzumab Biosimilar Approved by NMPA
|
|
17 Aug 2020 |
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
|
|
15 Aug 2020 |
Memo Therapeutics AG and Northway Biotechpharma Collaborate on the Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for the Therapy of COVID-19
|
|
15 Aug 2020 |
FDA Approves Genentech’s Enspryng for Neuromyelitis Optica Spectrum Disorder
|
